Stock_Titan Posted - 04/11/24

$FTRE Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call https://www.stocktitan.net/news/FTRE/fortrea-announces-date-for-first-quarter-2024-financial-results-and-ga8zv2nlxik8.html

HimmyGuap Posted - 03/13/24

$FTRE 30% in 3 days, im out...enjoy amigos

HimmyGuap Posted - 03/13/24

$FTRE almost at 40, lfg

Doozio Posted - 03/12/24

$FTRE whuts this fresh 🥩? It’s better lucky then good n to born just beFOUR 🧠⏰. 👀 at that MNDY 🐑!!

HimmyGuap Posted - 03/12/24

$FTRE lol spoofin like cray cray

HimmyGuap Posted - 03/12/24

$FTRE nice

briefingcom Posted - 03/11/24

$FTRE: Fortrea (-2.1%), which was spun off from LabCorp $LH in July 2023, is heading lower after the contract research organization (CRO) reported a Q4 miss for both EPS and revenue. The company also announced it will divest its Enabling Services segment called Endpoint Clinical and its Fortrea Patient Access unit to private equity firm Arsenal Capital Partners, which specializes in building technology-rich healthcare companies. The deal is expected to close in Q2. Fortrea has reported two earnings reports as an independent company. This Q4 miss was a bit of a surprise following the company's solid upside in Q3. Despite the miss, Fortrea noted that it was pleased with its book-to-bill ratio for Q4 at 1.3x, bringing it to a book-to-bill of more than 1.27x for its first six months as an independent organization. https://www.briefing.com/story-stocks/archive/2024/3/11/fortrea-heads-lower-on-earnings-miss-also-announced-sale-to-focus-on-being-a-pureplay-cro-(ftre)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link

mikesterz7 Posted - 03/11/24

$FTRE Summary Revenue: Slight increase to $3,109.0 million for FY 2023 from $3,096.1 million in FY 2022. Net Loss: Reported GAAP net loss of $(3.4) million for FY 2023, a decrease from a net income of $192.9 million in FY 2022. Adjusted EBITDA: Decreased to $267.3 million for FY 2023 from $405.1 million in FY 2022. Book-to-Bill Ratio: Achieved 1.30x in Q4 2023, indicating potential revenue growth. 2024 Guidance: Revenue targeted between $3,140 million to $3,205 million with adjusted EBITDA of $280 million to $320 million. Divestiture: Agreement to sell Endpoint Clinical and Fortrea Patient Access for $345 million.

BlakeCanyon50 Posted - 03/11/24

$FTRE That’s a slight miss…

GetVector Posted - 03/11/24

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $AMPY, $FTRE.

briefingcom Posted - 03/11/24

$FTRE: Fortrea misses by $0.04, reports revs in-line; guides FY24 revs in-line; to divest endpoint clinical and patient access businesses https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240311064015FTRE&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

BullYa Posted - 03/11/24

$FTRE 📉 $25 soon

DonCorleone77 Posted - 03/11/24

$FTRE Fortrea to divest Endpoint Clinical, Fortrea Patient Access for $345M On March 9, 2024, the Company entered into an agreement to divest Endpoint Clinical and Fortrea Patient Access to Arsenal Capital Partners. More information about the transaction was made available in Fortrea's press release dated March 11, 2024.The purchase price for the transaction is $345 million, subject to customary purchase price adjustments, with $295 million to be paid at closing and $50 million to be paid upon achievement of certain transition-related milestones. The transaction is targeted to close in the second calendar quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.

DonCorleone77 Posted - 03/11/24

$FTRE Fortrea Holdings sees 2024 revenue $3.14B-$3.205B, consensus $3.2B For the full year 2024, the Company targets revenues in the range of $3,140 million to $3,205 million and adjusted EBITDA guidance in the range of $280 million to $320 million, excluding the impact of the planned transaction described below. The guidance assumes foreign currency exchange rates as of December 31, 2023, remain in effect for the forecast period. The Company's 2024 financial guidance and the planned transaction will be discussed during the Earnings Call at 9:00 am ET on March 11, 2024.

DonCorleone77 Posted - 03/11/24

$FTRE Fortrea Holdings reports Q4 adjusted EPS 19c, consensus 24c Reports Q4 revenue $775.4M, consensus $776.06M. "Fortrea successfully navigated the second half 2023 transforming a "division of a division" into a leader in clinical development," said Tom Pike, chairman and CEO of Fortrea. "Customers and employees have responded favorably to our patient-inspired purpose and our innovative solutions, combining leading science, technology and people. The planned divestiture of our Patient Access and Endpoint businesses strengthens our focus on Phase 1 to 4 Clinical Services. We are also pleased to put an important issue in the rear-view mirror. 2024 is an important year for us to continue demonstrating that we can deliver excellent results for customers while improving the financial results for the medium and longer term. I'm confident our talented global team will continue to execute our plans with discipline and focus."

DonCorleone77 Posted - 03/11/24

$FTRE Fortrea to divest Endpoint Clinical, Fortrea Patient Access to Arsenal Capital Fortre has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners. By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best-in-class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.

Stock_Titan Posted - 03/11/24

$FTRE Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance https://www.stocktitan.net/news/FTRE/fortrea-reports-fourth-quarter-and-full-year-2023-results-issues-ya3axwaqxr1r.html

Stock_Titan Posted - 03/11/24

$FTRE Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners https://www.stocktitan.net/news/FTRE/fortrea-signs-definitive-agreement-to-divest-endpoint-clinical-and-ygmlppbwz1pb.html

DrumsRock Posted - 03/11/24

$FTRE Emptiest board I've seen in a long time. C'mon ER!

swingingtech Posted - 02/21/24

$ALKS, $FTRE, $ARCT, $CSL https://wallstreetwaves.com/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-february-2024/

Stock_Titan Posted - 02/20/24

$FTRE Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion https://www.stocktitan.net/news/FTRE/fortrea-increases-patient-access-capabilities-and-cold-chain-z1fs47kedxsn.html

Stock_Titan Posted - 02/20/24

$FTRE Fortrea to Present at the Barclays 26th Annual Global Healthcare Conference https://www.stocktitan.net/news/FTRE/fortrea-to-present-at-the-barclays-26th-annual-global-healthcare-74307nvcpzvi.html

Price2Book Posted - 02/16/24

$FTRE will this be bought out? Yoooo-hoooo?

theflynews Posted - 02/14/24

Starboard takes new stakes in Fortrea, News Corp - $FTRE - https://thefly.com/permalinks/entry.php/FTREid3863641

Sowa5000 Posted - 3 months ago

$FTRE great potential!

TA_Kongen Posted - 01/19/24

$FTRE Long term monster in the making here. Also watching $WOLF for possible long term scale in.

shortvolumes Posted - 01/17/24

2024-01-16 Short sale volume (not short interest) for $FTRE is 49%. http://shortvolumes.com/?t=FTRE via @shortvolumes

StockAutomatePro Posted - 01/12/24

$FTRE Chart is suggesting a bearish outlook for the stock. We alerted the SELL signal at $33.61 and we were able to close this one with profit at $29.99🤙

cctranscripts Posted - 01/11/24

Fortrea Holdings Inc.'s Chief Executive Officer just picked up 27,827 shares https://www.conferencecalltranscripts.org/summary/?id=12861544 $FTRE

Price2Book Posted - 01/11/24

$FTRE whats the deal here, anybody home?